Harpreet Singh (via Allogeneic Cell Therapies Summit)
March 18, 2020 08:14 AM EDT
Deals
R&D

TCR play­er Im­mat­ics com­bines with Per­cep­tive’s blank check op­er­a­tor, scoop­ing $252M and gain­ing a list­ing on Nas­daq

John Carroll

Editor & Founder

Per­cep­tive Ad­vi­sors’ blank check com­pa­ny has inked a deal — and it’s land­ing right in the mid­dle of a glob­al pan­dem­ic that’s roil­ing the in­dus­try. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times